Schreiber S, Powell N, Reider F, et al. Efficacy of deucravacitinib, an oral, selective, tyrosine kinase 2 inhibitor, in patients with moderately to severely active ulcerative colitis and prior exposure to biologic therapy: Subanalysis from the phase 2 LATTICE-UC study. The gene discussed is TYK2; the disease is ulcerative colitis.